PURPOSE: The authors report acute toxicity in 14 patients with locally advanced head and neck squamous cell carcinoma treated with radiotherapy and cetuximab. MATERIALS AND METHODS: Data collection was performed prospectively on patients treated from September 2007 to March 2009. Treatment consisted of 64.8-70 Gy radiotherapy in conventional fractions and cetuximab. RESULTS: Two out of 14 patients did not complete the planned combined treatment; radiotherapy was temporarily suspended in six other patients. Seven of 12 patients received cetuximab until the end of radiotherapy. Treatment breaks were principally due to severe acute cutaneous or mucous toxicity. Any grade acneiform rash occurred in all patients. In-field G3-4 cutaneous toxicity occurred in five (36%) patients and G3-4 mucous toxicity in seven (50%). One patient died of sepsis. CONCLUSIONS: In our experience, severe acute toxic reactions are common in patients treated with radiotherapy and concurrent cetuximab, resulting in frequent breaks or incomplete treatment with potential reduction in disease control.
PURPOSE: The authors report acute toxicity in 14 patients with locally advanced head and neck squamous cell carcinoma treated with radiotherapy and cetuximab. MATERIALS AND METHODS: Data collection was performed prospectively on patients treated from September 2007 to March 2009. Treatment consisted of 64.8-70 Gy radiotherapy in conventional fractions and cetuximab. RESULTS: Two out of 14 patients did not complete the planned combined treatment; radiotherapy was temporarily suspended in six other patients. Seven of 12 patients received cetuximab until the end of radiotherapy. Treatment breaks were principally due to severe acute cutaneous or mucous toxicity. Any grade acneiform rash occurred in all patients. In-field G3-4 cutaneous toxicity occurred in five (36%) patients and G3-4 mucous toxicity in seven (50%). One patient died of sepsis. CONCLUSIONS: In our experience, severe acute toxic reactions are common in patients treated with radiotherapy and concurrent cetuximab, resulting in frequent breaks or incomplete treatment with potential reduction in disease control.
Authors: David I Pryor; Sandro V Porceddu; Bryan H Burmeister; Alex Guminski; Damien B Thomson; Kristine Shepherdson; Michael Poulsen Journal: Radiother Oncol Date: 2008-10-29 Impact factor: 6.280
Authors: Allen M Chen; Leon M Chen; Andrew Vaughan; Radhika Sreeraman; D Gregory Farwell; Quang Luu; Derick H Lau; Kerri Stuart; James A Purdy; Srinivasan Vijayakumar Journal: Int J Radiat Oncol Biol Phys Date: 2010-04-14 Impact factor: 7.038
Authors: James A Bonner; Paul M Harari; Jordi Giralt; Roger B Cohen; Christopher U Jones; Ranjan K Sur; David Raben; Jose Baselga; Sharon A Spencer; Junming Zhu; Hagop Youssoufian; Eric K Rowinsky; K Kian Ang Journal: Lancet Oncol Date: 2009-11-10 Impact factor: 41.316
Authors: Christian Giro; Bernhard Berger; Edwin Bölke; I Frank Ciernik; Frederic Duprez; Laura Locati; Sophie Maillard; Mahmut Ozsahin; Raphael Pfeffer; A Gerry Robertson; Johannes A Langendijk; Wilfried Budach Journal: Radiother Oncol Date: 2008-10-30 Impact factor: 6.280
Authors: Adam S Garden; Joshua A Asper; William H Morrison; Naomi R Schechter; Bonnie S Glisson; Merrill S Kies; Jeffrey N Myers; K Kian Ang Journal: Cancer Date: 2004-03-15 Impact factor: 6.860